Mindstate Design Labs

Mindstate Design Labs is a clinical-stage AI neuroengineering platform and drug development company focused on creating altered states of consciousness for mental health therapeutics. Their Osmanthus AI platform maps emotion, perception, and cognition by synthesizing psychoactive drug effect data with biochemical data to design emotionally targeted states. They are advancing lead and future programs intended to induce therapeutic emotional and cognitive states through psychoactive compounds.

Osmanthus is an AI-powered platform that maps the biological basis of emotion, perception, and cognition by synthesizing 60,000 human reports of psychoactive drug effects with biochemical data. It uses multi-agent large language models, specialized embedding models, Bayesian neural networks, and other statistical learning methods to connect psychoactive phenomenology with pharmacology. The pipeline centers on lead asset MSD-001, a pharmaceutical compound designed to temporarily enable significant emotional cognitive flexibility, with additional combinations and programs (e.g., MSD-X02 and MSD-XXX) targeting novel CNS pathways and high-throughput Osmanthus screening for single-molecule, multi-target psychoactive effects. The team includes experienced scientists and executives steering research and development toward clinical studies and future programs.

Who it’s for: Pharmaceutical companies and biotech organizations focused on psychedelic-assisted therapies and neuropsychiatric drug development, particularly those seeking AI-driven discovery platforms for emotion- and cognition-targeted treatments.

Clinical-stage; mentions human studies and lead program progression